Rebecca H Chisholm1, Tommaso Lorenzi2, Jean Clairambault3. 1. School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia. 2. School of Mathematics and Statistics, University of St Andrews, North Haugh, KY16 9SS, St Andrews, Scotland, United Kingdom. Electronic address: http://www.tommasolorenzi.com. 3. INRIA Paris, MAMBA team, 2, rue Simone Iff, CS 42112, 75589 Paris Cedex 12, France; Sorbonne Universités, UPMC Univ. Paris 6, UMR 7598, Laboratoire Jacques-Louis Lions, Boîte courrier 187, 4 Place Jussieu, 75252 Paris Cedex 05, France. Electronic address: jean.clairambault@inria.fr.
Abstract
BACKGROUND: Drug-induced drug resistance in cancer has been attributed to diverse biological mechanisms at the individual cell or cell population scale, relying on stochastically or epigenetically varying expression of phenotypes at the single cell level, and on the adaptability of tumours at the cell population level. SCOPE OF REVIEW: We focus on intra-tumour heterogeneity, namely between-cell variability within cancer cell populations, to account for drug resistance. To shed light on such heterogeneity, we review evolutionary mechanisms that encompass the great evolution that has designed multicellular organisms, as well as smaller windows of evolution on the time scale of human disease. We also present mathematical models used to predict drug resistance in cancer and optimal control methods that can circumvent it in combined therapeutic strategies. MAJOR CONCLUSIONS: Plasticity in cancer cells, i.e., partial reversal to a stem-like status in individual cells and resulting adaptability of cancer cell populations, may be viewed as backward evolution making cancer cell populations resistant to drug insult. This reversible plasticity is captured by mathematical models that incorporate between-cell heterogeneity through continuous phenotypic variables. Such models have the benefit of being compatible with optimal control methods for the design of optimised therapeutic protocols involving combinations of cytotoxic and cytostatic treatments with epigenetic drugs and immunotherapies. GENERAL SIGNIFICANCE: Gathering knowledge from cancer and evolutionary biology with physiologically based mathematical models of cell population dynamics should provide oncologists with a rationale to design optimised therapeutic strategies to circumvent drug resistance, that still remains a major pitfall of cancer therapeutics. This article is part of a Special Issue entitled "System Genetics" Guest Editor: Dr. Yudong Cai and Dr. Tao Huang.
BACKGROUND: Drug-induced drug resistance in cancer has been attributed to diverse biological mechanisms at the individual cell or cell population scale, relying on stochastically or epigenetically varying expression of phenotypes at the single cell level, and on the adaptability of tumours at the cell population level. SCOPE OF REVIEW: We focus on intra-tumour heterogeneity, namely between-cell variability within cancer cell populations, to account for drug resistance. To shed light on such heterogeneity, we review evolutionary mechanisms that encompass the great evolution that has designed multicellular organisms, as well as smaller windows of evolution on the time scale of human disease. We also present mathematical models used to predict drug resistance in cancer and optimal control methods that can circumvent it in combined therapeutic strategies. MAJOR CONCLUSIONS: Plasticity in cancer cells, i.e., partial reversal to a stem-like status in individual cells and resulting adaptability of cancer cell populations, may be viewed as backward evolution making cancer cell populations resistant to drug insult. This reversible plasticity is captured by mathematical models that incorporate between-cell heterogeneity through continuous phenotypic variables. Such models have the benefit of being compatible with optimal control methods for the design of optimised therapeutic protocols involving combinations of cytotoxic and cytostatic treatments with epigenetic drugs and immunotherapies. GENERAL SIGNIFICANCE: Gathering knowledge from cancer and evolutionary biology with physiologically based mathematical models of cell population dynamics should provide oncologists with a rationale to design optimised therapeutic strategies to circumvent drug resistance, that still remains a major pitfall of cancer therapeutics. This article is part of a Special Issue entitled "System Genetics" Guest Editor: Dr. Yudong Cai and Dr. Tao Huang.
Authors: Kunihiko Hinohara; Hua-Jun Wu; Sébastien Vigneau; Thomas O McDonald; Kyomi J Igarashi; Kimiyo N Yamamoto; Thomas Madsen; Anne Fassl; Shawn B Egri; Malvina Papanastasiou; Lina Ding; Guillermo Peluffo; Ofir Cohen; Stephen C Kales; Madhu Lal-Nag; Ganesha Rai; David J Maloney; Ajit Jadhav; Anton Simeonov; Nikhil Wagle; Myles Brown; Alexander Meissner; Piotr Sicinski; Jacob D Jaffe; Rinath Jeselsohn; Alexander A Gimelbrant; Franziska Michor; Kornelia Polyak Journal: Cancer Cell Date: 2018-11-21 Impact factor: 31.743
Authors: Kenneth J Pienta; Emma U Hammarlund; Robert Axelrod; Sarah R Amend; Joel S Brown Journal: Mol Cancer Res Date: 2020-03-31 Impact factor: 5.852
Authors: Grant R Howard; Kaitlyn E Johnson; Areli Rodriguez Ayala; Thomas E Yankeelov; Amy Brock Journal: Sci Rep Date: 2018-08-13 Impact factor: 4.379
Authors: Anyue Yin; Dirk Jan A R Moes; Johan G C van Hasselt; Jesse J Swen; Henk-Jan Guchelaar Journal: CPT Pharmacometrics Syst Pharmacol Date: 2019-08-09